Nat. Biotechnol. 22, 145–147 (2004).
On p. 145, CTLA4-Ig is described as having achieved “outstanding phase 3 results.” In fact, the data were from a phase 2 trial.
The online version of the original article can be found at 10.1038/nbt0204-145
About this article
Frontiers in Immunology (2018)